EUCTR2015-003639-37-GB进行中（未招募）1 期
A Phase Ib and II Open-Label, Multi-Center Study of MEDI4736 Evaluated in Different Combinations in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 27
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Age =18 years at the time of screening.
- •2. Written informed consent and any locally required authorization obtained from the patient/legal representative prior to performing any protocol-related procedures, including screening evaluations.
- •3. Histologically or cytologically confirmed metastatic PDAC, no more than 1 prior systemic chemotherapy regimen or treatment-naïve patients
- •4. Life expectancy = 12 weeks.
- •5. Eastern Cooperative Oncology Group 0 or 1
- •6. At least 1 lesion, not previously irradiated, that can be accurately measured at
- •baseline as =10 mm in the longest diameter (except lymph nodes, which must have short axis =15 mm) with computed tomography (CT) or magnetic resonance imaging (MRI) scan and that is suitable for accurate repeated measurements
- •-Patient should receive no more than 1 prior chemotherapy regimen or any other systemic therapy for recurrent/metastatic PDAC.
- •7. Adequate organ and bone marrow function as defined below:
- •? Hemoglobin =9 g/dL
- •? Albumin =3 g/dL
- •? Absolute neutrophil count =1500/mm3
- •? Platelet count =100000/mm3
- •? Serum bilirubin =1.5 × the upper limit of normal (ULN). ?
- •ALT and AST =2.5 × ULN; for patients with hepatic metastases, ALT and AST =5 × ULN
- •Serum creatinine =1.5 mg/dL or calculated creatinine clearance =40 mL/min
- •8. Evidence of post-menopausal status or negative urinary or serum pregnancy test for female premenopausal patients
- •9. Mandatory tumor biopsy at screening
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 7
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 12
排除标准
- •1. Any concurrent chemotherapy, investigational product , biologic, or hormonal therapy for cancer treatment.
- •2. Receipt of any investigational anticancer therapy within 28 days or 5 half-lives, whichever is shorter, prior to the first dose of study treatment.
- •3. Concurrent enrollment in another clinical study, unless it is an observational (noninterventional) clinical study or during the follow-up period of an interventional study.
- •4. Receipt of last dose of an approved anticancer therapy within 21 days prior to the first dose of study treatment.
- •5. Major surgical procedure (as defined by the Investigator) within 21 days prior to the first dose of IP
- •6. Patients weighing less than 30 kg.
- •7. History of leptomeningeal carcinomatosis
- •8. Ascites requiring intervention
- •9. Brain metastases or spinal cord compression
- •10. Any unresolved toxicity NCI CTCAE Grade =2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria.
- •11. Current or prior use of immunosuppressive medication within 14 days before the first dose of MEDI4736. with exceptions that Intranasal, inhaled, or topical steroids; or local steroid injections; Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or equivalent; Steroids as premedication for hypersensitivity reactions and chemotherapy induced nausea and vomiting.
- •12.Current or prior use of immunosuppressive medication within 14 days before the first dose of MEDI4736
- •13. History of organ transplant that requires use of immunosuppressive agents.
- •14. Active autoimmune disorders , or prior documented severe autoimmune or inflammatory disorders requiring immunosuppressive treatment
- •- Prior exposure to immune-mediated therapy
- •- Has received any potent and moderate cytochrome P450 (CYP)3A4 inhibitors, potent and moderate CYP3A4 inducers, P-glycoprotein substrates (digoxin and dabigatran), breast cancer resistance protein substrates (topotecan), sensitive CYP2B6 substrates (bupropion and efavirenz), warfarin and coumarin derivatives, or herbal supplements within 14 days of the first dose of study treatment
- •15. Uncontrolled intercurrent illness
- •16. Other malignancy within 5 years except for noninvasive malignancies such as cervical carcinoma in situ, non-melanomatous carcinoma of the skin, prostate cancer or ductal carcinoma in situ of the breast that has/have been surgically cured
- •17. Mean QT interval corrected for heart rate using Fridericia’s formula (QTcF) =470 ms calculated from 3 ECG reports
- •18. History of active primary immunodeficiency.
- •19. Active infection including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus.
- •20. Active infection including hepatitis B, hepatitis C, or human immunodeficiency virus (HIV).
- •21. Receipt of live attenuated vaccine within 30 days prior to the first dose of IP.
- •22. Female patients who are pregnant or breastfeeding, or male or female patients of reproductive potential who are not employing an effective method of birth control (see Section 3.8).
- •23. Known allergy or hy
研究者
相似试验
进行中（未招募）
1 期
A Study Evaluating the Safety, Pharmacokinetics (what the body does to a drug), and Efficacy of Mosunetuzumab given subcutaneously (SC) or intravenously (IV) plus Lenalidomide (+Len) in Patients with Follicular LymphomaCTIS2023-507236-20-00F. Hoffmann-La Roche AG187
招募中
1 期
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination with Other Anti-Cancer Therapies in Patients with Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer with a KRAS G12C Mutationtreated Advanced or Metastatic Non-Small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code: 10059515Term: Non-small cell lung cancer metastatic Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864CTIS2023-507171-22-00F. Hoffmann-La Roche AG166
进行中（未招募）
1 期
Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 as Monotherapy or in Combination in Myeloid Leukemia Patients.Treatment Naïve or Relapsed/Refractory Acute Myeloid LeukemiaEUCTR2018-003857-73-GBAstraZeneca AB130
进行中（未招募）
1 期
A Study of Glofitamab (RO7082859) and Atezolizumab or Polatuzumab Vedotin (Plus A Single Pretreatment Dose of Obinutuzumab) in Adult Patients with Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma Glofitamab Imaging Sub-Study NP39488/IMG: A Study of Glofitamab (Plus A Single Pretreatment Dose of Obinutuzumab) Using 89ZR-DF-IAB22M2C as CD8 Tracer in Adult Patients with Relapsed/Refractory B-Cell Non-Hodgkin’s LymphomaCTIS2023-505222-34-00F. Hoffmann-La Roche AG211
进行中（未招募）
1 期
An Efficacy and Safety Study of JNJ-42756493 in Participants with Urothelial CancerEUCTR2014-002408-26-ATJanssen-Cilag International NV180